Search results
-
World Lung 2025 – Candel looks to a new agla-vec use
… that's relevant since this same study disappointed at ASCO 2024 when a poster revealed an ORR of just 11% among 45 …
- 05/19/2026 - 19:49 -
Novocure’s Lunar eclipse
… NSCLC + supportive care, vs supportive care Data at ASCO 2024: hit primary endpoint, time to intracranial …
- 05/19/2026 - 19:49 -
Ivonescimab back in tune
… disclosure highly relevant to the global trial. At ASCO 2024 Harmoni-A showed a highly statistically … Harmoni-A OS data Source: ASCO 2024. Akeso’s latest disclosure, which was …
- 05/19/2026 - 19:49 -
Arcus reaches the end of the road for etrumadenant
… a path forward based on the phase 1/2 Arc-9 trial, which at ASCO 2024 showed a 73% reduction in the risk of death with … January 2024 investment reshuffle. Arc-9 data at ASCO 2024 Source: company presentation. …
- 05/19/2026 - 19:49 -
5,000 patients later Roche scraps its TIGIT
… cards since the molecule put up dismal phase 1 data at ASCO 2024 , so the main surprise will be what took Roche so … RG6614 USP1 inhibitor (ex KSQ) Disappointed in ph1 at ASCO 2024 RO7589831/ RG6457 Werner helicase …
- 04/16/2026 - 07:02 -
Sino takes out the rest of Merck’s partner
… China ph1/2 in solid tumours (monotx & combos); data at ASCO 2024: 13% ORR (2/16) with monotx LM-168 …
- 05/19/2026 - 19:49 -
AbbVie's telisotuzumab conjugate take two
… relapsed colorectal cancer, where first-in-human data at ASCO 2024 showed 2.4mg/kg or higher dose scoring a 38% ORR …
- 05/19/2026 - 19:49 -
AbbVie gets a cMet niche
… 2nd-line+ solid tumours, incl CRC (+/- Avastin) Data at ASCO 2024 in CRC (>35% ORR in high cMet expressers at doses …
- 05/19/2026 - 19:49 -
Qilu nabs a new B7-H3 contender
… In a Chinese phase 1/2 solid tumour trial reported at ASCO 2024, MHB088C produced a 61% overall response rate …
- 05/19/2026 - 19:49 -
Ivonescimab goes post-checkpoint
… chemo; data due mid-2025 Chemo combo, vs chemo; data at ASCO 2024 2nd-line NSCLC (post PD-(L)1) (none) …
- 05/19/2026 - 19:49
